ArticleInternational journal of clinical and experimental medicine2015
Clinical role of circulating miR-223 as a novel biomarker in early diagnosis of cancer patients.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review.Advances in therapy · 2021Pooled it
- MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives.World journal of gastroenterology · 2018Pooled it
- Serum microRNA signatures and metabolomics have high diagnostic value in gastric cancer.BMC cancer · 2018Pooled it
- Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis.Oncotarget · 2017Pooled it
- MicroRNAs as current diagnostic biomarkers and potential therapeutic targets in allergic and non-allergic rhinitis - A functional characterization.Current allergy and asthma reports · 2026Review
- Cell-free Nucleic Acid as Promising Diagnostic Biomarkers for Gastric Cancer: a Systematic Review.Journal of Cancer · 2024Article
- Ginsenoside Rh2 inhibits thyroid cancer cell migration and proliferation via activation of miR-524-5p.Archives of medical science : AMS · 2022Article
- Low serum miR-223 expression predicts poor outcome in patients with acute myeloid leukemia.Journal of clinical laboratory analysis · 2020Article
- MicroRNA-223 Regulates Retinal Function and Inflammation in the Healthy and Degenerating Retina.Frontiers in cell and developmental biology · 2020Article
- Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer.Annals of gastroenterological surgery · 2020Article
- Article
- Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9.Oncotarget · 2017Article
- The effect of circulating miR-223 on surveillance of different cancers: a meta-analysis.OncoTargets and therapy · 2017Article
- Noncoding RNAs in gastric cancer: Research progress and prospects.World journal of gastroenterology · 2016Review
- miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma.Journal of bone oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent diagnostic procedures of cancers are invasive and non-specific. MicroRNAs (miRNAs) have become promising molecular markers for gastric cancer (GC) predication. However, there have been inconsistencies in the literature regarding the suitability of circulating miRNAs for early detection of cancers.
methodsWe performed a comprehensive meta-analysis to integrate an evaluation index for diagnostic accuracy of miR-223 in diagnosing cancer patients. Furthermore, we conducted an independent validation set of 50 gastric cancer patients and 50 healthy controls comparing miR-223 expression. We also analyzed miR-223 expression in vitro.
resultsA total of 11 studies met the inclusion criteria and therefore included in this meta-analysis. We found that miR-223 yielded a pooled area under ROC curve (AUC) of 0.89 (sensitivity: 81%, specificity: 84%) in discriminating cancer from controls. In our validation test, plasma miR-223 levels in GC patients were significantly higher than that in healthy controls (P<0.01). ROC curve analysis showed that AUC was 0.812 with a sensitivity of 70% and specificity of 80%. Moreover, the expression trend of miR-223 in plasma samples was in accordance with that of tissue and cell samples.
conclusionCurrent evidences suggested that plasma miR-223 could be a reliable and non-invasive biomarker for cancer diagnosis. Further large-scale prospective studies are necessary to validate their potential applicability in human cancer diagnosis.
Indexed as
Identifiers
26629240PMC4659128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.